TransCode Therapeutics, Inc. (RNAZ) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
Analysts estimate Earnings Per Share (EPS) of $-4,398.24 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-47.14 vs est $-4,398.24 (beat +98.9%). Analyst accuracy: 0%.
RNAZ Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to TransCode Therapeutics, Inc. in the past 3 months
EPS Estimates — RNAZ
0%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024
Actual –$47.14
vs Est –$4,398.24
▲ 9,230.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — RNAZ
Revenue Trend
Analysts expect stable revenue going forward.
